Antibiotic Resistance Market is expected to cross USD 13,146 Million by 2025 at a CAGR of 5.8%.
Antibiotic resistance occurs naturally, but the misuse of antibiotics in humans would increase the growth of antimicrobial resistance. Bacteria become resistant to the antibiotics that are designed to kill them. Increasing antibiotic-resistant infections and emergence of multi-drug resistant pathogens will enhance the growth of antibiotic resistance market. For instance, in 2016, approximately 49,000 people developed multi-drug resistant TB globally, and drug resistance is complicating the fight against HIV as well as malaria.
There is an extensive occurrence of antibiotic resistance among 5,00,000 people with suspected bacterial infections across 22 countries in the antibiotic resistance marker. As a result, increasing the occurrence of antibiotic resistance would drive the demand for the global antibiotic resistance market.
- Rising antibiotic drug resistance infections is expected to drive the growth of the market. For instance, each year in the US, at least 2.8 million people get an antibiotic-resistant infection, and more than 35,000 people die.
- Rise in incidence of chronic and infectious disease is expected to drive the growth of the market. For instance, more than 17 million people were affected by contagious diseases globally.
- An increase in clinical developments of antibiotic resistance is expected to drive the growth of the market. For instance, as of June 2019, approximately 42 new antibiotic resistance with the potential to treat severe bacterial infections are in clinical development.
- Rise in global initiatives to control drug-resistance
- High medical costs. The cost of health care for patients suffering from resistant infections is higher than care for patients suffering from non-resistant infections due to the extended duration of illness, and increased usage of expensive drugs.
By Drug class
- Cephalosporins: They are class of β-lactam antibiotic resistance originally derived from Acremonium and are effective against a wide range of bacteria. They kill bacteria and have similar functions to that of penicillin.
- Combination Therapies: It includes fixed-dose combinations of beta-lactams and beta-lactamase inhibitors. This segment holds the largest market segment owing to the increased use of these therapies for gram-negative infections that have limited treatment options.
- Tetracyclines: Tetracyclines has been a widely used antibiotic since it has low toxicity and the broad spectrum of activity.
- Lipoglycopeptides: Telavancin, dalbavancin, and oritavancin are the most common types of lipoglycopeptides.
- Oxazolidinones: Linezolid is one of the newest oxazolidinones type of antibiotics used for the treatment of infections caused by Gram-positive bacterial pathogens.
- Others: Others include sulfonamide, vancomycin, among others.
- Complicated Urinary Tract Infection: Largest growing segment as Urinary tract infections (UTIs) are one of the most common types of infections, and at least one in two women and one in 10 men would experience a UTI in their life period. There were around 1,045 patients affected by UTI.
- Blood Stream Infections: Bloodstream infections cause high morbidity and mortality in humans.
- Complicated Intra-Abdominal Infections: Intra-abdominal infections are the second most common cause of infectious mortality in intensive care units.
- Clostridium Difficile Infections: Clostridium difficile infection leads to approximately 453,000 cases and 29,000 deaths every year in the US.
- Acute Bacterial Skin and Skin Structure Infections: There is an increase in hospitalization due to acute bacterial skin and skin structure infections caused by resistant pathogens that provide the need for new treatment options. Tedizolid phosphate, dalbavancin, and oritavancin were approved by the US Food and Drug Administration (FDA) in 2016.
- Hospital-Acquired Bacterial Pneumonia/Ventilator: Occurrence of pneumonia is most notably the top infectious cause of death in children under age five globally. In the US, there were nearly 700,000 emergency department visits and 50,622 deaths due to pneumonia in 2016.
- Community-Acquired Bacterial Pneumonia: This is one of the leading causes of death and hospitalization in both the US as well as abroad.
- Others: Others include tuberculosis, blood poisoning, gonorrhea, and foodborne diseases.
- Staphylococcus Aureus: Methicillin-resistant Staphylococcus aureus (MRSA) can cause difficult-to-treat staph infections because of resistance to some antibiotics. Around 323,700 patients were hospitalized due to this, and there were about 10,600 deaths in 2017.
- Streptococcus Pneumoniae: It causes pneumococcal disease. Approximately 9,00,000 estimated streptococcus pneumoniae infections were registered in 2016.
- Acinetobacter: Carbapenem-resistant Acinetobacter causes pneumonia, bloodstream, and urinary tract infections (UTI). Approximately 8,500 patients were affected, and about 700 deaths occurred due to this.
- Enterococcus: Enterococci can cause serious, including bloodstream, surgical site, and urinary tract infections. There were around 5,400 deaths in 2017 due to this infection.
- Hemophilus Influenzae: It causes pneumonia, meningitis, and bacteremia, that are primarily caused community-acquired pneumonia
- Pseudomonas Aeruginosa: P. aeruginosa infections usually occur in people with weakened immune systems and can be dangerous for patients with chronic lung diseases. Approximately 32,600 patients were hospitalized.
- Clostridium Difficile: Fastest growing segment as it is one of the most common healthcare-associated infections in the US. Approximately 223,900 cases of Clostridium difficile occurred in 2017, and at least 12,800 people died as a result of this.
- Pneumoniae: Largest growing segment. It was estimated that there were approximately 212,500 infections per year and about 70 deaths per year.
- Campylobacter: Campylobacter usually causes diarrhea, often bloody, fever, and abdominal cramps. 448,400 cases of campylobacter occurred in 2017, and at least 70 people died.
- Others: Others include salmonella, Neisseria gonorrhoeae, Enterobacteriaceae, among others.
- Hospitals & Clinics: The largest growing segment as the majority of treatment and procedures are carried out in hospitals. Additionally, in 2016, the average consumption of antibiotics for systemic use in hospitals was 2.1 defined daily doses (DDD) per 1,000 people per day.
- Research Organizations: They encourage the research & development of new antimicrobial drugs and diagnostics, thus would drive the growth of the market. Global Antibiotic Research & Development Partnership address global public health needs by delivering and developing new or improved antibiotic treatments.
- Others: Others include academic institutes, nursing homes, and emergency care centers.
- Americas: The largest regional market. Rising growth in the pharmaceutical sector, increasing adoption of antibiotic resistance, increasing the prevalence of infectious diseases are the significant factors that would drive the growth of the antibiotic resistance market in this region.
- Europe: Rising consumption of antibiotic resistance, high prevalence of infectious diseases, and rise in bacterial infections. These factors are anticipated to drive the growth of the antibiotic resistance market in this region.
- Asia-Pacific: The fastest-growing regional market in antibiotic resistance owing to the rising number of antibiotic-resistant infections and hospital-acquired infections. In Germany, an estimated 400,000 to 600,000 patients suffer from hospital-acquired infections each year.
- Middle East & Africa: Increasing healthcare expenditure and rising consumption of antibiotic resistance would drive the demand for the antibiotic resistance market in this region.
- Achaogen, Inc. (US)
- Basilea Pharmaceutica Ltd. (Switzerland)
- MELINTA THERAPEUTICS, INC. (US)
- PARATEK therapeutics (US)
- Seres Therapeutics (US)
- Theravance Biopharma (UK)
- Entasis Therapeutics (US)
- Tetraphase Pharmaceuticals (US)
- Nabriva Therapeutics plc (Ireland)
- NEMESIS BIOSCIENCE LTD (UK)
- Procarta Biosystems (England)
- Allecra Therapeutics (US)
USD 13,146 Million
(5.8%) : 2019-2025
Value (USD Million)
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Achaogen, Inc. (US), Basilea Pharmaceutica Ltd. (Switzerland), MELINTA THERAPEUTICS, INC. (US), PARATEK therapeutics (US), Seres Therapeutics (US), Theravance Biopharma (UK), Entasis Therapeutics (US),
Tetraphase Pharmaceuticals (US), Nabriva Therapeutics plc (Ireland), NEMESIS BIOSCIENCE LTD (UK), Procarta Biosystems (England),Allecra Therapeutics (US)
Key Market Opportunities
Increasing healthcare expenditureRising consumption of antibiotic resistance
Key Market Drivers
Rising antibiotic drug resistance infectionsRise in incidence of chronic and infectious diseaseIncrease in clinical developments of antibiotic resistance Rise in global initiatives to control drug-resistance
Frequently Asked Questions (FAQ) :
Antibiotic Resistance Market is expected to reach a valuation of more than USD 13.1 billion by 2025.
Antibiotic Resistance Market is expected to exhibit a strong 5.8% CAGR over the forecast period from 2019 to 2025.
Growing usage of antibiotics is the major driver for the Antibiotic Resistance Market.
The Americas are the largest regional market for antibiotic resistance.
Leading players in the Antibiotic Resistance Market include Achaogen, Seres Therapeutics, and Theravance Biopharma, among others.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.